LKPC(SH:600789) Xin Lang Cai Jing·2025-10-31 18:01Company Overview - Luyou Pharmaceutical was established on February 15, 1993, and listed on the Shanghai Stock Exchange on February 26, 1997. It is one of the four major antibiotic production bases in China, with a complete pharmaceutical industry chain and strong technical capabilities in chemical pharmaceuticals [1] Financial Performance - As of Q3 2025, Luyou Pharmaceutical reported revenue of 4.624 billion yuan, ranking 16th among 110 companies in the industry. The top company, East China Pharmaceutical, had revenue of 32.664 billion yuan, while the industry average was 2.8 billion yuan [2] - The net profit for the same period was 147 million yuan, placing the company 42nd in the industry. The leading company, Hengrui Medicine, reported a net profit of 5.76 billion yuan, with the industry average at 299 million yuan [2] Financial Ratios - The debt-to-asset ratio for Luyou Pharmaceutical as of Q3 2025 was 53.44%, down from 55.92% year-on-year, which is higher than the industry average of 35.26% [3] - The gross profit margin for the same period was 21.71%, slightly down from 21.82% year-on-year, and significantly lower than the industry average of 57.17% [3] Executive Compensation - The chairman, Peng Xin, received a salary of 1.1436 million yuan in 2024, a decrease of 223,100 yuan from 2023. The general manager, Dong Kun, earned 1.0301 million yuan, down 100,300 yuan from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 8.54% to 113,500. The average number of circulating A-shares held per shareholder increased by 9.33% to 7,915.14 [5]